Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy
OLP Admin
Our team at VIC recently published a review article in the Trends in Molecular Medicine Journal, under the guidance of Dr. Gemechu. Clinical trial data increasingly show that targeted immunotherapies such as antibodies, T-cells and vaccines improve outcomes when delivered in combination with the immunomodulatory drug (IMiD) derivatives lenalidomide or pomalidomide. We review these clinical […] The post Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy appeared first on V